July 02, 2025

Lean Body Mass–Based Oxaliplatin Dosing and Risk of Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer

In a French phase II trial (LEANOX) reported in the Journal of Clinical Oncology, Assenat et al examined survival outcomes and oxaliplatin-induced peripheral neurotoxicity risk associated with lean bo...

The ASCO Post

July 02, 2025

Can Genetic Testing Identify the Best Treatment for Metastatic, Castration-Resistant Prostate Cancer?

Patients with metastatic, castration-resistant prostate cancer (mCRPC) have a median overall survival of only about two to three years, but genomic sequencing is making inroads against that grim prognosis.

Roswell Park Comprehensive Cancer Center

July 01, 2025

Our Vision for the Future of Cancer Care

Since 1947, Dana-Farber has been at the forefront of blending exceptional cancer care with leading-edge, transformative science. At the core of what we do is a patient-centered approach with a singular focus — cancer care.

Dana-Farber

July 01, 2025

Survey Shows Inaccuracies in U.S. Perceptions of Testicular Cancer

Only about 13% of U.S. adults correctly reported that testicular cancer is most common among men younger than 40.

The ASCO Post

July 01, 2025

Metastatic Castration-Resistant Prostate Cancer: Comparison of Second-Line Regimens

As reported in The Lancet Oncology by Agarwal et al, the phase III CONTACT-02 trial examined the survival benefit of cabozantinib plus atezolizumab vs switch of androgen receptor pathway inhibitor (AR...

The ASCO Post

July 01, 2025

HER3-DXd in NSCLC Without EGFR-Activating Mutations

As reported in the Journal of Clinical Oncology by Steuer et al, findings in a cohort of a phase I trial indicated activity of the HER3-directed antibody-drug conjugate patritumab deruxtecan (HER3-DXd...

The ASCO Post

July 01, 2025

Dana-Farber Research News 07.01.2025

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from June 1 through June 15.

Dana-Farber

July 01, 2025

New Study Shows Tiny Cuts Could Improve Brain Surgery: A Simpler, Safer Way to Treat Brain Tumors

A new study from doctors at Miami Neuroscience Institute, part of Baptist Health, highlights a gentler way to perform brain surgery, one that uses small tools and avoids the need for large openings in the skull.

Baptist Health South Florida

June 30, 2025

Kidney Cancer Highlights from ASCO 2025

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates you need to know from ASCO 2025.

Dana-Farber